Case Reports
Vol. 4 No. 1 (2012): Reviews, Articles, Case Reports and Letters
Adjuvant corticosteroid therapy in hepatosplenic candidiasis-related IRIS
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: March 13, 2012
2621
Views
728
Downloads
1168
HTML
Authors
Hepatosplenic candidiasis (HSC) is a form of invasive fungal infection that occurs most commonly in patients with acute leukemia treated with chemotherapy and requires protracted antifungal therapy. Immune reconstitution inflammatory syndrome (IRIS) is best characterized as a dysregulated inflammatory responses triggered by rapid resolution of immunosuppression.
We present a child diagnosed with standard-risk precursor B cell-acute lymphoblastic leukemia who developed HSC and Candida-related IRIS during recovery of neutropenia associated with induction chemotherapy. Addition of corticosteroid therapy to antifungal treatment is associated with the resolution of the clinical symptoms and laboratory findingsDownloads
Download data is not yet available.
Citations
How to Cite
“Adjuvant corticosteroid therapy in hepatosplenic candidiasis-related IRIS” (2012) Mediterranean Journal of Hematology and Infectious Diseases, 4(1), p. e2012018. doi:10.4084/mjhid.2012.018.
